LH · Labcorp Holdings Inc.
$328.95
-0.30% last session
End-of-day data · close of 2026-10-23
Market cap
$27B
Enterprise value
$33B
Trailing P/E
27.2
Forward P/E
16.6
Dividend yield
1.0%
Beta
0.85
Avg volume
1M
Employees
71K
Daily Change %
-0.30%
5 Days Change
3.77%
10 Days Change
5.19%
30 Days Change
8.54%
60 Days Change
-2.56%
Month to Day Change
8.32%
Year to Day Change
32.48%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-21
Latest call per bank · past 12 months
UBS
Buy$380
+15.5% vs priceBarclays
Equal-Weight$330
+0.3% vs priceJP Morgan
Overweight$360
+9.4% vs priceMorgan Stanley
Overweight$338
+2.8% vs priceBank of America
Buy$320
-2.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-21 | Truist Securities | Maintains | Buy | $350 → $365 |
| 2026-09-11 | UBS | Maintains | Buy | $361 → $380 |
| 2026-09-11 | Barclays | Maintains | Equal-Weight | $320 → $330 |
| 2026-08-04 | Piper Sandler | Maintains | Neutral | $300 → $309 |
| 2026-08-03 | JP Morgan | Maintains | Overweight | $330 → $360 |
| 2026-07-31 | Morgan Stanley | Maintains | Overweight | $308 → $338 |
| 2026-07-31 | Truist Securities | Maintains | Buy | $320 → $350 |
| 2026-07-31 | Barclays | Maintains | Equal-Weight | $290 → $320 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 63 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 2.6% above the 50-day MA ($320.60).
- bullish: Price vs 200-day MA: Trading 15.7% above the 200-day MA ($284.21).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+1.97) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($338.61).
LH Price Chart
Loading chart for LH…
Fundamentals
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.